Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: The Utah Senate and House of Representatives voted unanimously Monday evening during a special session to send the proposal to Republican Gov. Gary Herbert’s desk. The measure would replace plans for an unusual state-run dispensary system with 14 privately run pharmacies and adopt protections for patients who are concerned they could be prosecuted for drug crimes, among other changes. Utah backtracked from the state-run dispensary after county attorneys expressed concern that such a system would put public employees at risk of being prosecuted under federal drug laws. Republican Senate Majority Leader Evan Vickers, who drafted the law, said his team is “doing everything we can” to improve patient access and have product ready by next March. Some lawmakers said they still have heartburn over certain aspects of the bill, sharing reservations about product distribution and a looming fear of federal prosecution. Democratic Sen. Derek Kitchen said he’s concerned patients in rural parts of the state may have to pay more to access marijuana. Before the House vote, Republican Rep. Keven Stratton suggested Utah seek a federal waiver to protect the state program from prosecution under federal drug laws. Marijuana is banned at the federal level, though a congressional amendment blocks the Justice Department from interfering with states’ medical marijuana programs. The measure dictated that the courts may not treat a medical marijuana patient differently than someone who uses any other prescribed, controlled substance. Another change prohibited the state from issuing cultivation and pharmacy licenses to legislators. “A lot of money flows through this industry, some back to legislators,” Vickers said. “We don’t want legislators to have undue influence in an industry they want to have ownership in.” Debates in the chamber reflected ongoing tensions over amendments regarding distribution and prosecution of drug crimes. During a tense public hearing last week, members of the conservative group Utah Eagle Forum lamented the loss of the state-run dispensary system, while some medical marijuana advocates raised concern that there wouldn’t be enough private dispensaries to meet growing patient demand. An earlier version of the law imagined 12 privately run dispensaries instead of the state-run system. In the same meeting, a proposal outlining patient protections caused an emotional back-and-forth between conservative attorneys who argued parents couldn’t take care of children while using marijuana and patients who said the drug makes them better caretakers and helps them manage their pain. Utah residents voted to legalize medical marijuana via ballot measure in November. The revised law became effective in December after a compromise that secured the support of The Church of Jesus Christ of Latter-day Saints and some marijuana advocates. However, the deal drew backlash from other advocates as it banned many marijuana edibles, placed additional restrictions on growing cannabis and made fewer medical conditions eligible for treatment with pot. Other changes addressed issues with land ordinances for cultivation facilities and marijuana research at in-state universities. Marijuana advocates said they are optimistic about the changes adopted. “There’s a light at the end of the tunnel, we see legislators working together, and they’re willing to work out a plan for patients,” Desiree Hennessy, director of the Utah Patients Coalition, said. Republican Rep. Brad Daw acknowledged the measure as a good first step but expects additional changes to the program in January. “I have close friends who, for them, cannabis is the only option, it relieves the kind of pain they have ... we have every right and responsibility to work toward a law that allows medical cannabis to patients who need it,” he said. “Is this bill perfect? Of course not. Is this done? No, it’s not.”

A: Utah lawmakers approve changes to medical cannabis law.
****
Q: Since 2011, Pugh received $500,000 selling her illustrated books to the University of Maryland Medical System, a $4 billion hospital network that’s one of the largest private employers in the state. Since the arrangement was exposed by The Baltimore Sun earlier this month, she’s stepped down from the volunteer board and returned her most recent payment of $100,000 for the hard-to-find books. She also defended her actions and portrayed press inquiries as a “witch hunt.” A Democrat who became mayor in 2016 and represented some of Baltimore’s poorest areas in the state’s Senate before that, Pugh is the public face of the still-unfolding debacle. But the Baltimore mayor — who served on the UMMS board since 2001 and once sat on a state Senate committee that funded the major health network — is hardly the only influential Marylander connected to the board or the medical system facing questions. One-third of the UMMS board members received compensation through the medical system’s arrangements with their businesses, a revelation that Gov. Larry Hogan has called “appalling.” Two other members of the board also resigned, and four others went on voluntary leave while the system reviews governance practices. The president and CEO of the University of Maryland Medical System has recently been sent on a temporary leave of absence. Maryland Comptroller Peter Franchot said Tuesday that an independent audit is urgent to understand how many “self-dealing” arrangements there have been over the years. In Pugh’s case, there needs to be a thorough examination of whether a product was actually delivered, he said. “I describe it as juvenile, this arrangement where she was providing or not providing books — no receipts, no contracts, no procurement. It was simply a $500,000 gift to her from the University of Maryland Medical System,” Franchot asserted in a phone interview. The slim “Healthy Holly” books, sharing tips on nutrition and exercise, were meant to be distributed to schools and daycares. However, the Sun has reported that 50,000 copies are unaccounted for, leading to widespread speculation that a good chunk were never printed in the first place. In recent days, fewer than 9,000 copies were tracked down collecting dust in a warehouse of Baltimore’s school district, which has described Pugh’s children’s books as “unsolicited” donations. The city library system, daycare programs and booksellers can’t find copies. “Healthy Holly: Exercising is Fun” is unavailable on Amazon, where the only reviews for the book are entries of people savaging Pugh’s ties with UMMS. In a written statement, Pugh has defended her lucrative book deal with UMMS, saying it started as a passion project. “I recall passing the time by thumbing through the first book before an UMMS meeting. One my colleagues loved it and thought it would help advance children’s health,” she said in a recent statement. Pugh has since cancelled all public appearances and her spokespeople say she was hospitalized over the weekend with pneumonia. They say she will address the matter more once her health improves. Criticism of UMMS and of Pugh — who faces a 2020 Democratic primary for re-election in a city dominated by a single party’s political machine — has been intense. The Washington Post’s editorial board asserted the UMMS had a “get-rich-quick program” for many of its board members, with Pugh’s involvement painted as an egregious case of “political sleaze.” Meanwhile, UMMS and Pugh have not provided clarity on the whereabouts of the 100,000 copies of the “Healthy Holly” series books or definitive proof they were published and distributed. A spokeswoman for the university-based health network says their communications team was “working hard on all of the inquiries.” The medical system had classified the “Healthy Holly” purchases as grants in federal filings. Some critics say the various statements made by Pugh and others regarding the arrangements with UMMS board members are absurd on so many levels that it’s hard to know where to begin. “Whatever Pugh does, she is going to be operating under a very, very big cloud for a long time,” said Donald Norris, professor emeritus of public policy at the University of Maryland Baltimore County. “This is an unethical lapse of humongous proportions — $500,000 worth.” ___ Follow McFadden on Twitter: https://twitter.com/dmcfadd

A: Baltimore mayor’s $500K book deal draws intense criticism.
****
Q: The story goes into some detail about the cost of Folotyn, which is extraordinarily high. The story also does a great job of comparing the cost of the drug to other expensive cancer drugs. Costs were the main focus of the story. The story adequately quantitifes the benefits of Folotyn, which are not that impressive. The story provides the percentage of patients with reductions in tumor size and the median time that the benefits lasted. The story does not mention any potential harms of Folotyn. Although the primary focus of the story realtes to the drug’s cost, it would have desriable to provide a brief comment on the toxicity of the drug as well. The addition of the information would help the reader place the value of the drug into a better perspective. According to the package insert, 44% of patients treated in the clinical trial suffered from a serious side effect of the drug The story describes the evidence to support Folotyn, which is rather thin. The story mentions one clinical trial that showed a reduction in tumor size in some participants, but that to date, the drug has not been shown to prolong longevity. The quote from a member of the FDA advisory board that recommended approval provides an excellent overview and counterpoint to the comments of the company spokesperson. The story accurately represents the seriousness and prevalence of peripheral T-cell Lymphoma, which is quite rare and serious. The story quotes multiple stakeholders, including experts from the drug manufacturer, a large insurance company, and lymphoma researchers. The provide valuable diversity of perspectives on this controversial issue. The story clearly states that there are no alternatives to Folotyn for this particular indications, but compares the price of the drug to several other expensive cancer drugs. The story should have emphasized that Folotyn was studied in patients who have relapsed and a comparison with currently used regimens is not available. The story clearly states that Folotyn is not currently available but that the manufacturer plans to market the drug in January. The story clearly states that Folotyn is new. It could have stated that a host of older and less expensive treatment options are currently available. Because the story quotes mutliple experts, the reader can assume the story did not rely on a press release as the sole source of information.

A:
Questioning a $30,000-a-Month Cancer Drug
****